Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic obstructive pulmonary disease, Pulmonary rehabilitation, Nasal high flow
Brief summary
Chronic obstructive pulmonary disease (COPD) is a major cause of disability and mortality worldwide. This systemic disease progressively leads to dyspnea and exercise capacity impairment. Pulmonary rehabilitation effectively improves exercise capacity, dyspnea and quality of life in patients with COPD. However, its benefits progressively fade over time due to several factors such as the lack of regular exercise activity, dyspnea, airway secretions, hematosis impairment and acute exacerbations which can lead to hospitalization and accelerated muscle wasting. Nasal high flow (NHF) is a support used to deliver heated and humidified high flow air (up to 60 L/min) through nasal canula providing promising physiological benefits such as positive airway pressure or upper airway carbon dioxide washout. It can be used in association with oxygen and offers the advantage to overtake the patient's inspiratory flow, providing a stable inspired fraction of oxygen. Nasal high flow has widely been studied in pediatric and adult intensive care units and seems better than conventional oxygen therapy and as effective as noninvasive ventilation with regards to mortality to treat hypoxemic acute respiratory failure. More recently, several studies have shown that long-term nasal high flow could contribute to improve exercise capacity, dyspnea, airway secretion removal, hematosis, reduced acute exacerbations and subsequent hospitalizations in patients with COPD. Based on these results, the primary aim of this study is to assess whether long-term nasal high flow treatment can help COPD patients to better maintain their endurance capacity following a course of pulmonary rehabilitation.
Detailed description
Experimental design: Patients achieving their last pulmonary rehabilitation session will be approached to participate in this study. Eligible patients who agree to participate in the study and sign informed consent will perform two baseline visit assessments: First visit: Incremental cardiopulmonary exercise testing. Second visit: Other baseline assessment (see outcome section), including a constant workload exercise testing at 75% of the maximal workload achieved during the incremental exercise testing. Then, patients will then be randomized to one of the following two arms: * Nasal high flow, * Usual care. After 6 months, patients will be invited to perform the same assessment as during the second baseline visit.
Interventions
DEVICENasal high flow
See arm description.
Sponsors
ADIR Association
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Assessors will be unaware of the patient's allocation.
Intervention model description
Single blind randomized study.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Chronic obstructive pulmonary disease stage III to IV; * With or without long-term oxygen therapy; * Having completed a course of pulmonary rehabilitation within the last 4 weeks (at least 18 sessions).
Exclusion criteria
* Did not complete a course of pulmonary rehabilitation; * Using noninvasive ventilation or constant positive airway pressure treatment; * Tracheostomy; * Nasal high flow intolerance; * Pregnancy or likely to be; * Unable to consent; * Patients under guardianship.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endurance capacity | The endurance capacity will be assessed at baseline | Patients will perform a constant workload exercise testing at 75% of the maximal workload achieved during the incremental cardiopulmonary exercise testing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of life: Chronic Obstructive Pulmonary Disease Assessement Test | The quality of life will be assessed at baseline and post-intervention for a total time frame of 6month | Quality of life will be assessed using the Chronic Obstructive Pulmonary Disease Assessement Test |
| Exacerbations | The number of exacerbations will be assessed for a total time frame of 6month | The number of chronic obstructive pulmonary disease self reported exacerbations experienced by the participants during the 6 months period of follow-up will be assessed. |
| Hospitalizations | The number of hospitalizations will be assessed for a total time frame of 6month | The number of chronic obstructive pulmonary disease related hospitalizations experienced by the participants during the 6 months period of follow-up will be assessed. |
| Muscle function (1) : quadriceps muscle (rectus femoris) cross-sectional area | The quadriceps muscle thickness will be assessed at baseline | The quadriceps muscle thickness will be assessed using echographies. |
| Muscle function (2) : bioimpedance | The overall muscle function using bioimpedance will be assessed post-intervention (after 6months) | The overall muscle function will be assessed using bioimpedance (free fat mass minus total body water) |
| Exercise capacity | The distance performed during the six-minute walk test will be assessed at baseline | Exercise capacity will be assessed using the six minutes walk test distance. |
| Respiratory muscle function (1) : maximal inspiratory pressure | Maximal inspiratory pressure will be assessed at baseline | — |
| Respiratory muscle function (2) : maximal expiratory pressure | Maximal expiratory pressure will be assessed at baseline | — |
| Quality of life: Saint George's Respiratory Questionnaire | The quality of life will be assessed at baseline | Quality of life will be assessed using the Saint George's Respiratory Questionnaire. The score range from 0 (worst quality of life) to 100 (optimal quality of life). |
| Parasternal electromyogram | Parasternal electromyogram will be assessed at baseline | Parasternal electromyogram will be used to assess central output during maximal inspiratory and expiratory pressure measurement as during the sniff test. Moreover, parasternal electromyogram will be assessed both at rest and during nasal high flow (30L/min, 34°C). |
| Physical activity (1) : steps per day | Steps per day will be assessed during 14 days following inclusion | The number of steps per day will be recorded over a course of 14 week days using an activity monitor. |
| Physical activity (2) : time spent during activities superior to 3 metabolic equivalent per day | The time spent during activities superior to 3 metabolic equivalent per day will be assessed 14 days following inclusion | The time spent during activities superior to 3 metabolic equivalent per day will be over a course of 14 week days |
| Quality of sleep (1) : Visual Analogue Scale | The quality of sleep using a Visual Analogue Scale will be assessed at baseline | The quality of sleep will be assessed using a aVisual Analogue Scale (ranging from 0 to 10 with 10 indicating higher sleep quality). |
| Quality of sleep (2) : pittsburgh scale | The quality of sleep using the pittsburgh scale will be assessed at baseline | The quality of sleep will be assessed using the pittsburgh scale which has been validated to assess sleep quality. The scale range from 0 (major sleep difficulties) to 21 (no difficulty). |
| Adherence to treatment : days of utilization during the follow-up | The number of days that the nasal high flow device was used throughout the follow-up will be assessed post-intervention in the nasal high flow arm for a total time frame of 6 months | The data will be retrieved from the nasal high flow device |
| Adherence to treatment : hours of utilization per day | The number of hours of utilization per day throughout the follow-up will be assessed post-intervention in the nasal high flow arm for a total time frame of 6 months | The data will be retrieved from the nasal high flow device |
| Respiratory muscle function (3) : sniff test | Sniff test will be assessed at baseline | — |
Countries
France
Outcome results
None listed